Form 4: AN2 Therapeutics Director Kabeer Aziz Granted Stock Options Valued at $1.19 Per Share

AN2 Therapeutics, Inc. Director Kabeer Aziz was granted 19,111 stock options with an exercise price of $1.19 per share, vesting on March 31, 2026.

Summary

• Kabeer Aziz, a Director of AN2 Therapeutics, Inc. (ANTX), acquired 19,111 derivative securities in the form of stock options.
• The transaction occurred on May 22, 2025.
• Each option has an exercise price of $1.19.
• The options are for Common Stock, with 19,111 shares underlying the derivative security.
• The options were granted at a price of $0 per derivative security.
• The options will vest on March 31, 2026, contingent upon Mr. Aziz's continuous service to the company.
• The expiration date for these options is May 21, 2035.
• Following this transaction, Kabeer Aziz directly beneficially owns 19,111 derivative securities.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally viewed positively as it aligns insider interests with shareholder value creation and signals continued commitment to the company. It does not, however, provide direct insight into operational or financial performance.

Positives

• The grant of stock options to Director Kabeer Aziz aligns his financial interests with those of the shareholders, as the value of his options increases with the company's stock price.
• The acquisition of options by an insider can signal confidence in the company's future prospects and long-term growth potential.

Risks

• The vesting of the 19,111 option shares is subject to Kabeer Aziz providing continuous service through March 31, 2026, meaning the options could be forfeited if service is terminated before this date.

Future Outlook

The document indicates a future vesting event for the granted stock options on March 31, 2026, contingent on the director's continued service.

Industry Context

In the biotechnology and pharmaceutical sectors, granting stock options to directors and executives is a common practice to attract and retain talent, align management incentives with shareholder interests, and encourage long-term commitment to the company's success, particularly given the long development cycles inherent in the industry.

Comparison to Industry Standards

• The grant of stock options as a form of compensation for directors is a standard practice across various industries, including biotechnology, serving to align the interests of the director with the long-term performance of the company's stock.
• The vesting schedule, contingent on continuous service, is a typical mechanism to ensure retention and sustained commitment from key personnel.

Related Party Transactions

• The grant of stock options to Kabeer Aziz, a Director of AN2 Therapeutics, Inc., constitutes a related party transaction as it involves a company insider.

Stakeholder Impact

• Shareholders: The grant of options to a director can be seen as a positive signal of insider confidence and aligns the director's incentives with shareholder returns, potentially encouraging long-term value creation.
• Employees: While not directly impacting all employees, such compensation structures for leadership can set a precedent for performance-based incentives within the company.

Next Steps

• Kabeer Aziz's continuous service to AN2 Therapeutics, Inc. until March 31, 2026, for the options to vest.
• Potential exercise of the options by Kabeer Aziz at or after the vesting date and before the expiration date.

Key Dates

Keywords

AN2 Therapeutics, ANTX, Kabeer Aziz, Stock Options, Insider Trading, SEC Form 4, Director Compensation, Equity Grant, Beneficial Ownership, Biotechnology, Pharmaceuticals